Klotho Neurosciences shares rise 10.40% intraday following rebrand to Greenland Mines Ltd., acquisition of $68B Skaergaard Project, and strategic expansion into natural resources.

Klotho Neurosciences surged 10.40% intraday, driven by the company's announcement of a name change to Greenland Mines Ltd. and stock code update to GRML, reflecting its strategic expansion into natural resources. The company also announced the acquisition of Greenland Mines Corp., gaining control of the Skaergaard Project—a world-class undeveloped palladium, gold, and platinum deposit valued at approximately $68 billion. Klotho Neurosciences focuses on developing cell and gene therapies for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer's, with its core product KLTO-202 for ALS receiving FDA orphan drug designation.